Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITCI Intra-Cellular Therapies	$131.87	$131.87	$66.26 ▼ $131.98	$14.05B	0.69	1.52 million shs	N/A
LNTH Lantheus	$81.49 +0.9%	$84.72	$73.11 ▼ $126.89	$5.64B	0.11	1.01 million shs	1.39 million shs
SMMT Summit Therapeutics	$20.60 -3.4%	$23.39	$6.78 ▼ $36.91	$15.30B	-1.06	3.65 million shs	14.07 million shs
TEVA Teva Pharmaceutical Industries	$16.76 +1.2%	$16.72	$12.47 ▼ $22.80	$19.22B	0.6	10.25 million shs	8.94 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	-0.04%	+92.54%
LNTH Lantheus	0.00%	+2.90%	+7.92%	-16.51%	+1.49%
SMMT Summit Therapeutics	0.00%	+0.19%	+10.40%	+6.79%	+164.10%
TEVA Teva Pharmaceutical Industries	0.00%	-1.25%	-0.09%	+8.90%	+3.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ITCI Intra-Cellular Therapies	0.9056 of 5 stars	1.1	0.0	4.5	0.0	1.7	0.6
LNTH Lantheus	4.3589 of 5 stars	3.5	1.0	4.2	1.9	2.5	1.9
SMMT Summit Therapeutics	2.6335 of 5 stars	4.4	1.0	0.0	2.7	1.7	0.0
TEVA Teva Pharmaceutical Industries	4.0219 of 5 stars	4.6	3.0	0.0	2.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
LNTH Lantheus	3.00	Buy	$130.50	60.14% Upside
SMMT Summit Therapeutics	2.77	Moderate Buy	$35.09	70.34% Upside
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.13	43.99% Upside

Current Analyst Ratings Breakdown

Latest LNTH, TEVA, SMMT, and ITCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
LNTH Lantheus	$1.53B	3.68	$7.09 per share	11.49	$15.65 per share	5.21
SMMT Summit Therapeutics	$700K	21,855.72	N/A	N/A	$0.53 per share	38.87
TEVA Teva Pharmaceutical Industries	$16.54B	1.16	$3.36 per share	4.98	$4.74 per share	3.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
LNTH Lantheus	$312.44M	$3.52	23.15	12.91	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.37	0.86	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest LNTH, TEVA, SMMT, and ITCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
LNTH Lantheus	0.49	5.74	5.46
SMMT Summit Therapeutics	N/A	10.63	10.63
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ITCI Intra-Cellular Therapies	92.33%
LNTH Lantheus	99.06%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ITCI Intra-Cellular Therapies	2.60%
LNTH Lantheus	2.00%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

LNTH, TEVA, SMMT, and ITCI Headlines

Recent News About These Companies

Allspring Global Investments Holdings LLC Purchases 5,186,592 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29 at 5:32 AM | marketbeat.com

Sequoia Financial Advisors LLC Increases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29 at 4:14 AM | marketbeat.com

Asset Management One Co. Ltd. Reduces Stock Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 29 at 3:44 AM | marketbeat.com

Achmea Investment Management B.V. Sells 122,509 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 28 at 5:26 AM | marketbeat.com

UBS Group Lowers Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $23.00

June 28 at 2:33 AM | americanbankingnews.com

Teva’s CEO shares ‘Pivot to Growth’ progress

June 27 at 6:41 PM | fiercepharma.comF

Zacks Research Has Optimistic Outlook of TEVA Q1 Earnings

June 27 at 6:39 AM | marketbeat.com

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada

June 27 at 4:54 AM | ophthalmologytimes.comO

Teva Releases Q2 2025 Aide Memoire

June 26, 2025 | financialpost.comF

Teva Releases Q2 2025 Aide Memoire

June 26, 2025 | globenewswire.com

Teva Pharmaceutical Industries (NYSE:TEVA) Given New $23.00 Price Target at UBS Group

June 26, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by GHP Investment Advisors Inc.

June 26, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd (TEVA) Announces Upcoming Q2 2025 Financial Results Release ...

June 25, 2025 | gurufocus.com

Teva points to long-term efficacy of Ajovy in migraine

June 25, 2025 | thepharmaletter.comT

Teva Pharmaceutical Industries Ltd. to Announce Second Quarter 2025 Financial Results on July 30, 2025

June 25, 2025 | quiverquant.comQ

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

June 25, 2025 | financialpost.comF

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

June 25, 2025 | globenewswire.com

Teva Pharmaceutical Industries Ltd. - Page 2 - The New York Times

June 25, 2025 | nytimes.com

Retirement Systems of Alabama Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 25, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd: Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic ...

June 24, 2025 | finanznachrichten.de

Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress - Nasdaq

June 24, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH, TEVA, SMMT, and ITCI Company Descriptions

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Lantheus NASDAQ:LNTH

$81.49 +0.75 (+0.93%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$79.50 -1.99 (-2.44%)

As of 04:27 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$20.60 -0.72 (-3.38%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$20.77 +0.17 (+0.84%)

As of 04:09 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$16.76 +0.20 (+1.18%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$16.94 +0.19 (+1.10%)

As of 04:29 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time